Showing results (31-40 of 58) with videos related to
Sort By:
Pageof 6
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 21, 2010
[Tolerability and safety of docetaxel plus cyclophosphamide as adjuvant chemotherapy for axillary lymph node-negative breast cancer--JECBC04 trial]Naohito Yamamoto, Toshio Tabei, Kenichi Inoue, et al.Molecular and Clinical Oncology|November 26, 2021
Synchronous early-stage breast cancer and axillary follicular lymphoma diagnosed by core needle biopsy: A case reportRyotaro Eto, Rikiya Nakamura, Naohito Yamamoto, et al.Clinical Breast Cancer|October 29, 2017
Radiofrequency Ablation of Breast Cancer: A Retrospective StudyToshikazu Ito, Shoji Oura, Shinji Nagamine, et al.Oncology|November 20, 2013
Final results of a safety and efficacy trial of preoperative sequential chemoradiation therapy for the nonsurgical treatment of early breast cancer: Japan Clinical Oncology Group Study JCOG0306Hirofumi Mukai, Toru Watanabe, Michihide Mitsumori, et al.Journal of Cosmetic Dermatology|April 3, 2025
Altered Ceramide Profile of Facial Sensitive Skin: Disordered Intercellular Lipid Structure Is Linked to Skin HypersensitivityTaisei Joichi, Hiroyuki Yoshida, Hiroaki Katsukura, et al.Japanese Journal of Clinical Oncology|July 2, 2011
Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancerHiroji Iwata, Nobuaki Sato, Norikazu Masuda, et al.Breast Cancer Research and Treatment|April 15, 2014
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpressionMasashi Ando, Hideko Yamauchi, Kenjiro Aogi, et al.Breast Cancer (Tokyo, Japan)|August 25, 2006
Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patientsMayumi Iwakawa, Shuhei Noda, Shigeru Yamada, et al.Breast Cancer (Tokyo, Japan)|August 21, 2025
Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysisMasato Takahashi, Hiroyuki Yasojima, Tomofumi Osako, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|October 13, 2006
[Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial]Muneaki Sano, Toshio Tabei, Kimito Suemasu, et al.Pageof 6